<?xml version="1.0" encoding="UTF-8"?>
<results title="testTrace">
 <result pre="causing this disease (SARSâ€�CoVâ€�2). The first clinical trials have been" exact="testing" post="repurposed drugs that show promising antiâ€�SARSâ€�CoVâ€�2 effects in cultured"/>
 <result pre="in the clinical inclusion criteria, including the possibility of early" exact="treatment" post="that may be essential for therapy efficacy in patients"/>
 <result pre="with a documented MoA against SARSâ€�CoVâ€�2 in clinical trials. Successful" exact="treatment" post="will probably be based on multitherapies with antiviral compounds"/>
 <result pre="treatments with robust statistical tools and to identify the best" exact="treatment" post="for each Covidâ€�19 stage. This review describes different candidate"/>
 <result pre="action of some promising antiviral drugs. Drug repurposing for Covidâ€�19" exact="treatment" post="is in progress, and the mode of action of"/>
 <result pre="approved drugs used for other diseases or selected by virtual" exact="screening" post="are indicated in yellow. The black question marks indicate"/>
 <result pre="based on existing drugs that were developed to treat viral" exact="infection" post="or other diseases. Moreover, the many different clinical trials"/>
 <result pre="different clinical trials currently in progress (more than 2400) are" exact="testing" post="a limited set of drugs, alone or in combination.15"/>
 <result pre="the risk of depletion of pharmacy stocks needed for the" exact="treatment" post="of other pathologies. On the other hand, the emergence"/>
 <result pre="Covidâ€�19 contain neutralizing antibodies (Abs) that can limit SARSâ€�CoVâ€�2 viral" exact="infection" post="inâ€‰vitro.17 Moreover, administration of plasma from convalescent patients has"/>
 <result pre="entry into the cell.34 This strategy seems to limit SARSâ€�CoVâ€�2" exact="infection" post="in cell culture, but the stability of the soluble"/>
 <result pre="other cellular receptors, such as CD147, also can block viral" exact="infection" post="in cell culture, and the direct interaction between CD147"/>
 <result pre="includes umifenovir (Arbidol), an antiviral molecule initially developed for the" exact="treatment" post="of influenza infection.62 Interestingly, umifenovir has a broad spectrum"/>
 <result pre="viruses63 and stimulating the immune response.38 Moreover, umifenovir inhibits SARSâ€�CoVâ€�2" exact="infection" post="in vitro with an IC50 of 10 Î¼M.39 Although"/>
 <result pre="TABLE 1 Main antiviral molecules currently being tested against SARSâ€�CoVâ€�2" exact="infection" post="Compounds Target/MoA Tests in vitro (CoV) Clinical trials SARSâ€�CoVâ€�2"/>
 <result pre="fidelity.67 While nucleoside analogs have been successfully used for the" exact="treatment" post="of other viral diseases, the situation is complicated in"/>
 <result pre="SARSâ€�CoV showed that the antiviral activity is dependent on early" exact="treatment" post="after infection.47 Remdesivir is incorporated into nascent RNA by"/>
 <result pre="hypotension, remdesivir was licensed in May 2020 as an emergence" exact="treatment" post="against SARSâ€�CoVâ€�2. The cytidine analog Î²â€�dâ€�N4â€�hydroxycytidine (NHC) also is"/>
 <result pre="72 and should be assessed in clinical trials. Another potential" exact="treatment" post="is the guanine analog favipiravir (Tâ€�705) that was initially"/>
 <result pre="and Ebola virus.78, 79, 80 Favipiravir was approved for influenza" exact="treatment" post="in Japan in 2014, and is currently assessed for"/>
 <result pre="in Japan in 2014, and is currently assessed for Covidâ€�19" exact="treatment" post="in several clinical trials.42, 51 The preliminary results suggest"/>
 <result pre="is sofosbuvir, a broadâ€�acting antiviral approved for hepatitis C virus" exact="infection" post="management. A recent study showed that sofosbuvir triphosphate is"/>
 <result pre="REPOSITIONING STRATEGIES FOR COVIDâ€�19 TREATMENT The fastest option for the" exact="treatment" post="of Covidâ€�19 is the identification of already approved drugs"/>
 <result pre="often speculative, and the efficacy and clinical doses required for" exact="treatment" post="in patients with Covidâ€�19 are unknown, due to the"/>
 <result pre="interferon (IFN) could be used during the early stages of" exact="infection" post="to boost the innate immune response and promote viral"/>
 <result pre="trials, but results are not available yet. However, as SARSâ€�CoVâ€�2" exact="infection" post="may also be accompanied by a dysregulated immune response"/>
 <result pre="response leading to a massive production of proâ€�inflammatory cytokines, IFN" exact="treatment" post="could have unexpected effects.5, 83, 84, 85, 86 Indeed,"/>
 <result pre="in RECOVERY clinical trial and shown first promising results. Indeed," exact="treatment" post="with Dexamethasone reduces death by oneâ€�third to oneâ€�fifth.91 3.2"/>
 <result pre="to SARSâ€�CoVâ€�2 infection.102 More recently, it has been shown that" exact="treatment" post="target this pathway is not associated with higher severity"/>
 <result pre="TABLE 2 Main repositioning molecules currently being tested against SARSâ€�CoVâ€�2" exact="infection" post="Compounds Target/MoA Tests in vitro (CoV) Clinical trials SARSâ€�CoVâ€�2"/>
 <result pre="No data Vonoprazan PPI (39) No data Ivermectin Limits viral" exact="infection" post="(99) No data Oseltamivir Neuraminidase inhibitor No data No"/>
 <result pre="proton pump inhibitors, such as omeprazole and vonoprazan, reduce the" exact="infection" post="of cells by SARSâ€�CoVâ€�2.39, 64 In addition, chloroquine and"/>
 <result pre="and hydroxychloroquine (HCQ), which have been extensively used for the" exact="treatment" post="of malaria with known safety and efficacy, also limit"/>
 <result pre="vesicles, and lysosomes.106 These molecules significantly reduce SARSâ€�CoV and SARSâ€�CoVâ€�2" exact="infection" post="inâ€‰vitro.48, 93, 94, 95, 106, 107 However, a recent"/>
 <result pre="with some adverse cardiac effects. Many clinical studies are currently" exact="testing" post="these molecules,97, 98 and their initial results are controversial.110"/>
 <result pre="site in the spike protein of SARSâ€�CoVâ€�2 is essential for" exact="infection" post="of human lung cells. Mol Cell. 2020;78(4):779â€&quot;784. 32362314 12BelouzardS,"/>
 <result pre="The effectiveness of convalescent plasma and hyperimmune immunoglobulin for the" exact="treatment" post="of severe acute respiratory infections of viral etiology: a"/>
 <result pre="Med Chem. 2008;15(10):997â€�1005.18393857 39TouretF, GillesM, BarralK, et al. in vitro" exact="screening" post="of a FDA approved chemical library reveals potential inhibitors"/>
 <result pre="WitE, FeldmannF, CroninJ, et al. Prophylactic and therapeutic remdesivir (GSâ€�5734)" exact="treatment" post="in the rhesus macaque model of MERSâ€�CoV infection. Proc"/>
 <result pre="J Med. 2020;382:2327â€&quot;2336. 32275812 51CaiQ, YangM, LiuD, et al. Experimental" exact="treatment" post="with favipiravir for COVIDâ€�19: an openâ€�label control study. Engineering,"/>
 <result pre="56ChuCM, ChengVCC, HungIFN, et al. Role of lopinavir/ritonavir in the" exact="treatment" post="of SARS: initial virological and clinical findings. Thorax. 2004;59(3):252â€�256.14985565"/>
 <result pre="of the index patient who caused tertiary transmission of COVIDâ€�19" exact="infection" post="in Korea: the application of lopinavir/ritonavir for the treatment"/>
 <result pre="COVIDâ€�19 infection in Korea: the application of lopinavir/ritonavir for the" exact="treatment" post="of COVIDâ€�19 infected pneumonia monitored by quantitative RTâ€�PCR. J"/>
 <result pre="mutagen. Nat Med. 2000;6(12):1375â€�1379.11100123 66PruijssersAJ, DenisonMR. Nucleoside analogues for the" exact="treatment" post="of coronavirus infections. Curr Opin Virol. 2019;35:57â€�62.31125806 67FeldJJ, HoofnagleJH."/>
 <result pre="67FeldJJ, HoofnagleJH. Mechanism of action of interferon and ribavirin in" exact="treatment" post="of hepatitis C. Nature. 2005;436(7053):967â€�972.16107837 68FerronF, SubissiL, Silveira De"/>
 <result pre="virus replication and delays disease progression in a robust mouse" exact="infection" post="model. PLoS Negl Trop Dis. 2016;10(5):e0004695.27163257 76DelangL, Segura GuerreroN,"/>
 <result pre="macaques. PLoS Med.2018;15(3):e1002535.29584730 79OestereichL, LÃ¼dtkeA, WurrS, RiegerT, MuÃ±ozâ€�FontelaC, GÃ¼ntherS. Successful" exact="treatment" post="of advanced Ebola virus infection with Tâ€�705 (favipiravir) in"/>
 <result pre="WurrS, RiegerT, MuÃ±ozâ€�FontelaC, GÃ¼ntherS. Successful treatment of advanced Ebola virus" exact="infection" post="with Tâ€�705 (favipiravir) in a small animal model. Antiviral"/>
 <result pre="Postâ€�exposure efficacy of oral Tâ€�705 (favipiravir) against inhalational Ebola virus" exact="infection" post="in a mouse model. Antiviral Res. 2014;104:153â€�155.24462697 81collab: Shannon"/>
 <result pre="How to reduce the likelihood of coronavirusâ€�19 (CoVâ€�19 or SARSâ€�CoVâ€�2)" exact="infection" post="and lung inflammation mediated by ILâ€�1. J Biol Regul"/>
 <result pre="et al. Chloroquine is a potent inhibitor of SARS coronavirus" exact="infection" post="and spread. Virol J. 2005;2(1):69.16115318 94KeyaertsE, VijgenL, MaesP, NeytsJ,"/>
 <result pre="and projection of optimized dosing design of hydroxychloroquine for the" exact="treatment" post="of severe acute respiratory syndrome coronavirus 2 (SARSâ€�CoVâ€�2). Clin"/>
 <result pre="less toxic derivative of chloroquine, is effective in inhibiting SARSâ€�CoVâ€�2" exact="infection" post="in vitro. Cell Discov. 2020;6(1):16.32194981 97GaoJ, TianZ, YangX. Breakthrough:"/>
 <result pre="TianZ, YangX. Breakthrough: chloroquine phosphate has shown apparent efficacy in" exact="treatment" post="of COVIDâ€�19 associated pneumonia in clinical studies. Biosci Trends."/>
 <result pre="98GautretP, LagierJâ€�C, ParolaP, et al. Hydroxychloroquine and azithromycin as a" exact="treatment" post="of COVIDâ€�19: results of an openâ€�label nonâ€�randomized clinical trial."/>
 <result pre="angiotensinâ€�converting enzyme inhibitor or angiotensin receptor blocker use with COVIDâ€�19" exact="diagnosis" post="and mortality. JAMA. 2020;126:1671â€&quot;1681. 104HoffmannM, SchroederS, Kleineâ€�WeberH, MÃ¼llerMA, DrostenC,"/>
 <result pre="MÃ¼llerMA, DrostenC, PÃ¶hlmannS. Nafamostat mesylate blocks activation of SARSâ€�CoVâ€�2: new" exact="treatment" post="option for COVIDâ€�19. Antimicrob Agents Chemother. 2020;64:754â€&quot;820. 105HoffmannM, Kleineâ€�WeberH,"/>
 <result pre="April 27, 2020. 122MomekovG, MomekovaD. Ivermectin as a potential COVIDâ€�19" exact="treatment" post="from the pharmacokinetic point of view: antiviral levels are"/>
</results>
